Targeting the body’s complement system, part of the innate immune response, could be a solution for many diseases, including those of the skin and nervous system. But “inherent problems” with this ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...
Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and targeted cancers in ...
REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today ...
Dr. Lal PathLabs (DLPL) has announced the launch of complement testing laboratory, strengthening autoimmune diagnostics. This ...
Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...
Anemia caused by the autoimmune disorder cold agglutin disease now has its first approved treatment, a Sanofi drug designed to block a pathway key to the progression of this condition. The FDA’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback